Xalud’s technology was developed by Dr. Linda Watkins at the University of Colorado, Boulder. It is based on her pioneering insight that the basis for the strength and persistence of chronic pain is inflammation caused by activated glial cells.
XT-150’s efficacy is derived from its use of the potent, broad spectrum, anti-inflammatory protein interleukin-10 (IL-10). Existing anti-inflammatory products typically act through one or two pathways. IL-10 acts through multiple pathways including:
- suppressing TNF-α, IL-1β, IL-6 transcription, translation, processing, and release;
- down-regulating cytokine receptors and up-regulating antagonists; and
- inhibiting H2O2 and nitric oxide production.
This broad range of activity enables it to normalize glia cell activity and restore homeostasis. XT-150 uses proprietary variant of IL-10 that has demonstrated increased efficacy and duration of action as compared to wild type IL-10.
Inflammatory Joint Disease
Inflammatory joint diseases, including osteoarthritis and rheumatoid arthritis, are marked by patterns of inflammation, macrophage and glial cell activation, and immune system involvement that are similar to the patterns seen in the neuro-inflammatory diseases. IL-10 based therapies may be effective in treating these diseases.
By treating inflammation rather than blocking neuronal signaling, XT-150 avoids the side effects such as sedation and dizziness that are associated with all leading prescription pain drugs. Opioids are effective at blocking pain signaling, but they also activate glia cells. In essence they work against themselves by amplifying the same pain signaling they are attempting to block. This counter-productive effect may be responsible for the tolerance (and need for increasing dosages of opioids) often seen in chronic pain patients. By de-activating glia cells, XT-150 should prevent the development of tolerance in patients taking opioids and enable the same degree of pain relief to be obtained with lower dosages.